Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart check for delgocitinib: no cure, just safety data

NCT ID NCT05050279

Knowledge-focused Sponsor: LEO Pharma Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether the drug delgocitinib changes heart rhythms in 40 healthy adults. Participants took the drug or a placebo, and their heart activity was measured with ECGs. The goal was to check for possible heart risks, not to treat any disease. Since it involved healthy people and only measured safety, there was no direct benefit to participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

40 people

The number who actually took part.

Started

Sep 2021

Finished

Jan 2022

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Body mass index of ≥18.0 and \<30.0 kg/m2. * In good health, as judged by the investigator based on: medical history, physical examination, vital sign assessment, clinical laboratory evaluations . * ECG without any clinically relevant abnormal findings at both screening and baseline * No history of additional risk factors for torsades de pointes (for example, heart failure, hypokalaemia, family history of long QT syndrome). * Female subjects of childbearing potential and male subjects with a female partner of childbearing potential must be willing to use highlly effective methods of contraception. Exclusion Criteria: * Any disorder which is not stable and could: * Affect the safety of the subject throughout the trial. * Influence the findings of the trial. * Impede the subject's ability to complete the trial. * Use of any medication known to prolong the QT/QTc interval within 3 months or 5 half-lives of the drug, whichever is longer, prior to randomisation. * Any medications, including St. John's wort, known to chronically alter drug absorption or elimination processes within 30 days prior to dosing. * Current use of combined hormone contraceptives or combined hormonal replacement therapy. * Subjects who have smoked (use of any type of tobacco and nicotine containing products) within the last 3 months prior to screening. * History of chronic alcohol or drug abuse within 12 months prior to screening. * Receipt of any vaccine approved for SARS-CoV-2 within 4 weeks prior to baseline and/or 2 weeks after dose. * Receipt of live, attenuated vaccines within 4 weeks prior to baseline.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy

Contacts and locations

Locations

  • Labcorp Clinical Research Unit (CRU) Ltd, Springfield House, Hyde Street,

    Leeds, LS2 9LH, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.